These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 22434305)

  • 41. Bilateral femur fractures associated with short-term bisphosphonate use.
    Rifai A; Pourtaheri S; Carbone A; Callaghan JJ; Stadler CM; Record N; Issa K
    Orthopedics; 2015 Feb; 38(2):e139-42. PubMed ID: 25665120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequential subtrochanteric femoral fracture after atypical diaphyseal fracture in a long-term bisphosphonate user: a case report.
    Park KT; Lee KB
    Acta Chir Orthop Traumatol Cech; 2015; 82(2):157-60. PubMed ID: 26317188
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The 5-year follow-up of a cortical stress fracture resulting in a spontaneous atypical subtrochanteric femoral fracture in a female patient with severe osteoporosis and bisphosphonate therapy over 15 years.
    Haschka J; Kühne F; Muschitz C; Pirker T; Kocijan R; Bittighofer C; Trubrich A; Resch H
    Wien Klin Wochenschr; 2011 Nov; 123(21-22):684-7. PubMed ID: 21837437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
    Wadhwa VK; Weston R; Parr NJ
    BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration.
    Schmitz-Dräger BJ; Weiss C; Ebert T; Dörsam J; Bismarck E
    Urol Int; 2013; 90(3):329-33. PubMed ID: 23407093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Atraumatic bilateral femur fracture in long-term bisphosphonate use.
    Goddard MS; Reid KR; Johnston JC; Khanuja HS
    Orthopedics; 2009 Aug; 32(8):. PubMed ID: 19708622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.
    Nieves JW; Cosman F
    Curr Osteoporos Rep; 2010 Mar; 8(1):34-9. PubMed ID: 20425089
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bisphosphonate-associated femur fractures have high complication rates with operative fixation.
    Prasarn ML; Ahn J; Helfet DL; Lane JM; Lorich DG
    Clin Orthop Relat Res; 2012 Aug; 470(8):2295-301. PubMed ID: 22669553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Atypical femoral fracture associated with the use of bisphosphonates, an adverse drug reaction not to be missed].
    Ing Lorenzinit K; Meier R; Suva D; Dayer P; Desmeules J; Peter R
    Rev Med Suisse; 2012 Jun; 8(344):1238-42. PubMed ID: 22730621
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atypical fractures of the femur and ulna and complications of fracture healing in a 76-year-old woman with Sjögren's syndrome.
    Stathopoulos KD; Kosmidis C; Lyritis GP
    J Musculoskelet Neuronal Interact; 2011 Jun; 11(2):208-11; quiz 211. PubMed ID: 21625058
    [No Abstract]   [Full Text] [Related]  

  • 54. Outcomes between older adults with atypical and typical femoral fractures are comparable.
    Khow KS; Paterson F; Shibu P; Yu SC; Chehade MJ; Visvanathan R
    Injury; 2017 Feb; 48(2):394-398. PubMed ID: 27839798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Androgen deprivation in prostate cancer and the long-term risk of fracture.
    Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
    Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Annual zoledronic acid: is less more?
    Higano CS
    J Clin Oncol; 2007 Mar; 25(9):1026. PubMed ID: 17369565
    [No Abstract]   [Full Text] [Related]  

  • 57. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
    Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
    Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.
    Puhaindran ME; Farooki A; Steensma MR; Hameed M; Healey JH; Boland PJ
    J Bone Joint Surg Am; 2011 Jul; 93(13):1235-42. PubMed ID: 21776577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bilateral atypical femur fractures without bisphosphonate exposure.
    Szolomayer LK; Ibe IK; Lindskog DM
    Skeletal Radiol; 2017 Feb; 46(2):241-247. PubMed ID: 27900455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
    Izumi K; Mizokami A; Namiki M
    Clin Calcium; 2010 Feb; 20(2):175-81. PubMed ID: 20118508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.